Cerus Corporation raised its full-year 2026 product revenue guidance to a range of $229 million to $231 million, up from the prior $227 million to $231 million, and lifted its IFC revenue guidance to $23 million to $25 million from $22 million to $24 million. CFO Kevin Green reported second-quarter product revenue of $57.4 million, a 10% increase from the same period last year, with first-half product revenue up 16% to $111.1 million. U.S. IFC revenue rose approximately 20% to $6.7 million, and excluding a prior-year deferred revenue item, IFC growth would have been about 40% with demand up 43%. CEO Vivek Jayaraman highlighted the submission of a PMA for the INT200 platelet system to the FDA, with potential approval as early as the first half of 2027, and said top-line results from the Phase 3 RedeS trial for INTERCEPT red blood cells are expected in the fourth quarter. The company also completed a debt refinancing that reduced its term loan by $30 million and is expected to cut annual interest expense by up to $3.5 million, while gross margins are still seen in the low 50s for the year.
Cerus CorporationRaises 2026 product revenue and IFC guidance, reports strong Q2 results, and completes debt refinancing reducing interest expense.